HRT Financial LP, recognized as a 10% owner in Aditxt, Inc. (NASDAQ:ADTX), has formally disclosed a notable reduction in its equity position. The filing details a transaction executed on June 15, 2026, where the entity disposed of 2,114,344 shares of Aditxt common stock. This divestiture resulted in proceeds totaling approximately $29,600. The execution price for these shares was recorded at $0.014 per share, a valuation situated just above the security's 52-week low of $0.01. This price point underscores a severe depreciation in the stock's value over the preceding year, with the security experiencing a decline of nearly 100% from its 52-week high of $117.84. Post-transaction, HRT Financial LP maintains a direct holding of 344,964 shares in Aditxt.
Financial assessments of Aditxt reveal considerable pressures within the pharmaceutical preparations industry. Analysis indicates that the firm is rapidly depleting its cash reserves, a factor contributing to a "WEAK" financial health rating. Despite these headwinds, Aditxt has undertaken several strategic and operational maneuvers. The company has entered into a definitive business combination agreement for its subsidiary, Ignite Proteomics LLC, aiming to take the subsidiary public via a special purpose acquisition company. This transaction is structured to value Ignite at approximately $150 million, facilitating its transition into an independent publicly traded entity.
Corporate governance changes accompany these structural shifts. Aditxt has appointed Jeffrey M. Busch as its interim Chief Executive Officer, a role he will hold concurrently with his continued service as CEO of Ignite Proteomics. Furthermore, the company has secured stockholder approval for a 1-for-27 reverse stock split, scheduled to become effective on May 18, 2026. To bolster its liquidity, Aditxt has also raised $1.25 million through the private placement of senior unsecured promissory notes. These notes carry a 10% annual interest rate and are set to mature on September 30, 2026.
Regulatory compliance remains a focal point for the firm. Aditxt has successfully regained adherence to Nasdaq’s continued listing standards, as confirmed by correspondence from The Nasdaq Stock Market LLC. This compliance was achieved following the reporting of stockholders’ equity amounting to $3,953,682 in its Annual Report on Form 10-K. The interplay between insider selling, financial restructuring, and compliance efforts highlights the complex environment facing the pharmaceutical preparations sector, where valuation metrics and corporate governance are closely scrutinized by market participants.